Eli Lilly and Company
Eli Lilly and Company (LLY.SW) Stock Competitors & Peer Comparison
See (LLY.SW) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LLY.SW | CHF 720.00 | -7.69% | 554.8B | 39.60 | CHF 18.18 | +0.68% |
| RO.SW | CHF 332.00 | +0.73% | 264.3B | 20.69 | CHF 16.05 | +3.08% |
| ROG.SW | CHF 322.30 | +0.50% | 256.6B | 20.11 | CHF 16.03 | +3.04% |
| NOVN.SW | CHF 123.20 | +0.24% | 235.1B | 21.54 | CHF 5.72 | +1.95% |
| GSK.SW | CHF 19.98 | N/A | 101.6B | 18.76 | CHF 1.07 | N/A |
| BAYN.SW | CHF 36.97 | +0.00% | 36.3B | -11.13 | -CHF 3.32 | +0.28% |
| COPN.SW | CHF 86.90 | +0.58% | 1.4B | -413.81 | -CHF 0.21 | +2.21% |
Stock Comparison
LLY.SW vs RO.SW Comparison April 2026
LLY.SW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY.SW stands at 554.8B. In comparison, RO.SW has a market cap of 264.3B. Regarding current trading prices, LLY.SW is priced at CHF 720.00, while RO.SW trades at CHF 332.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY.SW currently has a P/E ratio of 39.60, whereas RO.SW's P/E ratio is 20.69. In terms of profitability, LLY.SW's ROE is +0.98%, compared to RO.SW's ROE of +0.41%. Regarding short-term risk, LLY.SW is less volatile compared to RO.SW. This indicates potentially lower risk in terms of short-term price fluctuations for LLY.SW.Check RO.SW's competition here